SNY
HealthcareSanofi
$47.51
$-0.72 (-1.49%)
Jan 5, 2026
Price History (1Y)
Analysis
Sanofi is a healthcare company operating within the drug manufacturers - general industry. With a market capitalization of $115.11B and revenue of $45.93B, it is a significant player in its sector. Sanofi has approximately 82,878 employees. The company's financial health indicates substantial profitability, with gross margin at 72.0%, operating margin at 28.7%, and profit margin at 19.8%. Return on equity stands at 8.8%, while debt to equity ratio is 29.59. Sanofi holds $8.91B in cash and has a current ratio of 1.06, indicating manageable liquidity. However, the company's net income (TTM) is $6.43B. Sanofi's valuation context shows a P/E ratio (TTM) of 15.68 and forward P/E of 9.60. Revenue growth over the past year has been -7.0%, while earnings growth has been 2.4%. The company offers a dividend yield of 455.0% and payout ratio of 73.9%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as a strategic alliance with the Department of Health Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Visit website →Key Statistics
- Market Cap
- $115.11B
- P/E Ratio
- 15.68
- 52-Week High
- $60.12
- 52-Week Low
- $44.62
- Avg Volume
- 2.39M
- Beta
- 0.40
- Dividend Yield
- 455.00%
Company Info
- Industry
- Drug Manufacturers - General
- Exchange
- NMS
- Country
- France
- Employees
- 82,878